Last reviewed · How we verify

Autologous MSCs — Competitive Intelligence Brief

Autologous MSCs (Autologous MSCs) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Regenerative Medicine / Orthopedics.

phase 3 Cell therapy Regenerative Medicine / Orthopedics Small molecule Live · refreshed every 30 min

Target snapshot

Autologous MSCs (Autologous MSCs) — Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León. Autologous mesenchymal stem cells (MSCs) are harvested from the patient's own bone marrow or adipose tissue and administered to promote tissue repair and modulate immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Autologous MSCs TARGET Autologous MSCs Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León phase 3 Cell therapy
Casgevy EXAGAMGLOGENE AUTOTEMCEL marketed Autologous genome-edited hematopoietic stem cell therapy BCL11A 2023-01-01
SkinTE SkinTE PolarityTE marketed Autologous cell therapy / Tissue-engineered product
ACP ACP Istituto Ortopedico Rizzoli marketed Cell therapy / Regenerative medicine product
Cellular Matrix / A-CP-HA Kit Cellular Matrix / A-CP-HA Kit Fundación Santiago Dexeus Font marketed Cell therapy / Regenerative medicine product
Licartin and CIK Licartin and CIK Tianjin Medical University Cancer Institute and Hospital marketed Monoclonal antibody (Licartin); Adoptive cell therapy (CIK) HAb18G/CD147 antigen (Licartin); Multiple (CIK cells)
MC MC Aivita Biomedical, Inc. marketed Mesenchymal stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

  1. Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
  2. Bone Therapeutics S.A · 1 drug in this class
  3. DiscGenics, Inc. · 1 drug in this class
  4. Celavie Bioscences, LLC · 1 drug in this class
  5. China Spinal Cord Injury Network · 1 drug in this class
  6. City of Hope Medical Center · 1 drug in this class
  7. Brainstorm-Cell Therapeutics · 1 drug in this class
  8. Dr. Grant M. Pagdin · 1 drug in this class
  9. FDA Office of Orphan Products Development · 1 drug in this class
  10. Biosolution Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Autologous MSCs — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-mscs. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: